Glioblastoma Multiforme Treatment Market Size, Share & Trends Analysis Report By Treatment (Radiation Therapy, Immunotherapy), By Drug Class, By End Use, By Region, And Segment Forecasts, 2021 - 2028

Report Overview

The global glioblastoma multiforme treatment market size was valued at USD 2.14 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 8.8% from 2021 to 2028. The growing prevalence of glioblastoma multiforme, increasing R&D, and favorable regulatory scenarios are among the factors anticipated to fuel the market growth. The presence of a strong pipeline is expected to act as a major driver for the glioblastoma multiforme (GBM) treatment market during the forecast period. The increasing incidence of brain tumors is expected to boost the growth of the market over the forecast period. According to Global Cancer Observatory, in 2020, the incidence of brain and CNS cancers was 308,102 globally and the number of deaths was 251,329 worldwide. Brain cancer is one of the deadliest forms of cancer.

Glioblastoma multiforme is the most common form of malignant tumor, accounting for up to 54% of gliomas and 16% of all primary brain cancers. The incidence of glioblastoma multiforme is high in adults compared to children and the risk of developing glioblastoma multiforme increases with age. 

The increasing approval for novel therapy and combination therapy is expected to drive the market in the coming years. For instance, in June 2019, the U.S. FDA approved Pfizer’s Zirabev, a biosimilar for Avastin, for the treatment of recurrent glioblastoma, NSCLC, and colorectal cancer, among others. In January 2020, the company launched its product in the U.S. Moreover, in November 2019, the U.S. FDA accepted Samsung’s BLA application for its SB8 bevacizumab biosimilar candidate, which will increase the potential to launch products in the coming years.

Tumor heterogeneity and variation in the patient-to-patient treatment approach are expected to contribute to an increase in the demand for a personalized treatment approach to manage glioblastoma multiforme. The approval of new treatments is expected to increase the life expectancy of patients living with glioblastoma multiforme. Furthermore, a special designation granted to investigational drugs by the FDA is expected to expedite the approval process and commercialization of novel therapy. For instance, in July 2020, the U.S. FDA granted fast track designation to Denovo biopharma’s DB102 (enzastaurin) for the treatment of patients newly diagnosed with glioblastoma.

Treatment Insights

Radiation therapy dominated the market with a revenue share of 37.6% in 2020 owing to the improved survival rates. Radiation therapy can be recommended as the first treatment or combined with chemotherapy and surgery. It is also effective and highly recommended for brain tumors in case of recurrence. The use of temozolomide along with radiotherapy makes the tumor more sensitive to radiation. This combination of therapy is more effective than radiation without temozolomide.

Surgery is the most common treatment for GBM, followed by radiation therapy and chemotherapy. This treatment plan is accepted as the standard of care. Moreover, the increasing use of targeted therapy to manage GBM is expected to fuel the segment growth during the forecast period. Rising research activities to develop novel targeted therapy for the disease are also anticipated to boost the segment growth.

Drug Class Insights

The others segment accounted for the largest revenue share of 66.4% in 2020. The other drugs segment includes drugs such as everolimus, corticosteroids, and 5-aminolevulinic acid (5-ALA). Corticosteroids are mainly prescribed to reduce the peritumoral vasogenic edema for symptomatic benefits. Dexamethasone is mainly prescribed due to its lack of mineralocorticoid activity. Furthermore, the use of corticosteroids may have immunosuppressive effects that emphasize the opportunities to target immune response for targeted therapy.

Bevacizumab is a targeted therapy approved for the treatment of recurrent and newly diagnosed GBM. Furthermore, in December 2017, the company received full approval from the U.S. FDA for bevacizumab for the treatment of adults with GBM. The medication is administered intravenously to stop the formation of new blood vessels that cut the blood supply and help reduce the tumor. Continuation in clinical studies to use bevacizumab with other therapies is expected to increase the usage of the drug for the management of GBM.

End-use Insights

The hospitals segment held the largest share of 49.2% in 2020 and is anticipated to maintain its lead during the forecast period. Hospitals are preferred by patients in terms of treatment accessibility and convenience. Moreover, a high number of surgeries performed to manage GBM and the complexity associated with the treatment are anticipated to drive the market.

The clinics segment is expected to grow at the fastest rate over the forecast period. Increasing adoption of noninvasive therapies, such as radiation therapy and tumor-treating fields therapy, is anticipated to drive the segment. Increasing adoption of noninvasive and patient-oriented treatment, such as external beam radiation therapy and tumor-treating fields therapy, is anticipated to boost segment growth. For instance, Johns Hopkins Medicine offers radiation therapy, tumor-treating fields therapy, and others for the treatment of brain cancer.

The ambulatory surgical centers segment is expected to witness lucrative growth over the forecast period. An increasing number of complex surgeries performed in an outpatient setting may increase the brain tumor resections at ambulatory surgical centers.

Regional Insights

North America accounted for the largest share of 43.6% in 2020. Government support for the development of the healthcare sector, high awareness about rare disorders, easy accessibility of quality medical facilities, and favorable reimbursement policies are among the key factors responsible for the regional market growth.

Asia Pacific is expected to register the fastest growth rate of 10.2% over the forecast period owing to various factors such as entry of generics of temozolomide in the market, improving economy, rising geriatric population, and growing investments in the healthcare sector. The presence of large unmet needs in the market, growing awareness about GBM, and the presence of a robust pipeline (molecules with the ability to bypass the blood-brain barrier) are among the key factors contributing to the regional market growth.

Key Companies & Market Share Insights

Key players in the GBM treatment market are focusing on R&D to develop advanced technology products to gain a competitive edge. Major players are engaged in mergers & acquisitions, and licensing & partnerships with an aim to strengthen their product portfolio, expand their manufacturing capacities, and provide competitive differentiation. For instance, in April 2021, Lineage Cell Therapeutics entered into a licensing agreement with Immunomic Therapeutics for the development of a cancer immunotherapy platform, allogeneic VAC, to treat glioblastoma multiforme. Under the agreement, an upfront payment of USD 2 million will be provided to Lineage, followed by USD 67 million as commercial milestones. Some prominent players in the global glioblastoma multiforme treatment market include:

• Merck & Co., Inc.

• Amgen, Inc.

• F. Hoffmann-La Roche Ltd.

• Pfizer Inc.

• Amgen, Inc.

• Teva Pharmaceutical Industries Ltd.

• Sun Pharmaceutical Industries Ltd.

• Arbor Pharmaceuticals, LLC

• Amneal Pharmaceuticals

• Karyopharm Therapeutics, Inc.

• Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)

Glioblastoma Multiforme Treatment Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2017 to 2028. For the purpose of this study, Grand View Research has segmented the global glioblastoma multiforme treatment market report on the basis of treatment, drug class, end-use, and region:

• Treatment Outlook (Revenue, USD Million, 2017 - 2028)

  • Surgery

  • Radiation Therapy

  • Chemotherapy

  • Targeted Therapy

  • Tumor Treating Field (TTF) Therapy

  • Immunotherapy

• Drug Class Outlook (Revenue, USD Million, 2017 - 2028)

  • Temozolomide

  • Bevacizumab

  • Lomustine

  • Carmustine Wafers

  • Others

• End-use Outlook (Revenue, USD Million, 2017 - 2028)

  • Hospitals

  • Clinics

  • Ambulatory Surgical Centers

• Regional Outlook (Revenue, USD Million, 2017 - 2028)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

    • Russia

  • Asia Pacific

    • China

    • India

    • Japan

    • South Korea

    • Australia

    • Singapore

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE